PRE-LAUNCH — Orders open APRIL 13 · Notify at Launch
RESEARCH

TB-500 10mg: The 43-Amino-Acid Actin Regulator for Advanced Preclinical Research

March 31, 2026 11 min read Cardiac & Tissue Repair Research

Most suppliers package TB-500 in 5mg vials—a format that forces researchers into multiple purchases for commonly cited loading/maintenance protocols. At Vantix Bio, we engineered our TB-500 format around how researchers actually use it: a loading phase followed by maintenance dosing, all from a single batch.

Our TB-500 10mg format supports many common shorter loading/maintenance designs in a single vial. No mid-cycle reordering. No batch variability between phases. One vial, one consistent research context.

Why TB-500 10mg?

  • One vial = loading + maintenance phases (no mid-cycle reorder)
  • $3.50/mg — verification-first pricing, no retail markup
  • ISO-17025 complementary-method verified (HPLC-DAD + LC-MS/MS)
  • Batch-level verification portal access
  • 18 peer-reviewed citations backing every claim in this article
Research Use Only: All mechanisms, applications, and findings discussed in this article refer to preclinical in vitro and animal model studies unless otherwise noted. TB-500 is not approved for human consumption, therapeutic use, or clinical application. It is sold strictly for laboratory research purposes. All cited references are linked in the References section.

Technical Specification

TB-500 10mg Analytical Profile

Full Name Thymosin Beta-4 (Tβ4) — synthetic analog
Amino Acid Count 43 amino acids (vs 15 AA for BPC-157)
Molecular Formula C212H350N56O78S [PubChem]
Molecular Weight 4963 Da [PubChem CID 45382195]
CAS Number 77591-33-4
Purity ≥98% (HPLC-DAD verified)
Verification ISO-17025 complementary methods (HPLC + LC-MS/MS)
Format 10mg lyophilized powder, sterile-filtered
Price $35/vial ($3.50/mg vs retail $5-8/mg)

The 10mg Rationale: Matching the Loading/Maintenance Paradigm

Unlike peptides commonly dosed daily, TB-500 research protocols typically follow a biphasic dosing paradigm: a higher-frequency loading phase followed by reduced-frequency maintenance. Commonly cited research ranges include:

At moderate dosing (2.5mg twice weekly for loading), a 4-week loading phase consumes approximately 20mg. But many shorter protocols—2 weeks of loading followed by 2-4 weeks of maintenance—fit comfortably within a single 10mg vial:

  1. 2-week loading at 2mg 2×/week: 8mg consumed
  2. Remaining 2mg for maintenance: 1 week at 2mg
  3. Alternative: 2-week loading at 2.5mg 2×/week with single 10mg vial

The industry-standard 5mg vial barely covers a single week of loading-phase dosing—forcing researchers to order multiple vials from potentially different batches. Our 10mg format provides meaningful protocol flexibility within a single-batch context.

Protocol-first design principle: TB-500's loading/maintenance paradigm demands more material upfront than steady-state daily dosing. The 10mg format provides the material density to support biphasic protocols without the batch-switching that introduces variability into longitudinal studies.

5mg vs 10mg TB-500: Side-by-Side Comparison

Feature Industry Standard (5mg) Vantix Bio (10mg)
Price per mg $5-8/mg retail
(~$6/mg avg across 23 vendors)		 $3.50/mg
Verification included
Loading phase coverage
(2.5mg 2×/week)		 1 week only
Requires 2nd vial immediately		 2 weeks loading
+ maintenance buffer
Batch consistency Requires 2-4 vials
Cross-batch variability		 Single vial per protocol
Eliminates variability
Purity verification Generic COA
(often batch-unverified)		 ISO-17025 complementary methods
Per-batch verification
Verification access PDF only
(if provided)		 Live portal + forensic watermarking
Instant batch lookup

Bottom line: Every batch is ISO-17025 verified with complementary HPLC + LC-MS testing. At $3.50/mg, that's not a discount — it's what verification-first pricing looks like without retail markup.

Start with verified material — no batch guessing.

View Latest Test Results Join Launch List (April 13)

Synthesis & Purity Standards: Forensic-Grade Verification

TB-500 is synthesized via solid-phase peptide synthesis (SPPS) using Fmoc chemistry. As a 43-amino-acid peptide—nearly three times the length of BPC-157—synthesis complexity increases significantly, making rigorous purification and verification even more critical.

Manufacturing Process

Each batch undergoes:

  1. Resin loading: Rink amide or Wang resin provides the solid support for C-terminal attachment
  2. Sequential coupling: 43 amino acids added in reverse sequence (C→N terminal direction) with careful monitoring for deletion sequences
  3. Cleavage & deprotection: TFA cocktail releases the peptide from resin and removes side-chain protecting groups
  4. Purification: Preparative HPLC removes truncated sequences, deletion peptides, and synthesis byproducts
  5. Lyophilization: Freeze-drying yields stable powder with <5% moisture content

Complementary-Method Verification

Every Vantix Bio batch is tested through ISO-17025 accredited laboratories using two complementary analytical methods:

1. HPLC-DAD (High-Performance Liquid Chromatography with Diode Array Detection)

Quantifies purity by separating TB-500 from impurities based on retention time. Our acceptance criterion: ≥98% purity with the target peptide peak representing >98% of total integrated area.

2. LC-MS/MS (Liquid Chromatography–Tandem Mass Spectrometry)

Confirms molecular identity by measuring mass-to-charge ratio. Observed molecular weight must match the theoretical MW of 4963 Da [PubChem] within acceptable tolerance. For a 43-amino-acid peptide, MS fragmentation analysis is particularly valuable for confirming full-length sequence integrity versus truncated variants.

Why complementary methods matter for TB-500: Longer peptides have greater risk of deletion sequences—variants missing one or more amino acids that may co-elute on HPLC. The beta-thymosin/WH2 module's multifunctional nature means even minor sequence alterations can affect actin-binding properties [2]. LC-MS/MS fragmentation catches what chromatography alone cannot, providing forensic-grade identity confirmation alongside purity quantification.

Mechanism of Action: Actin Regulation and Cell Migration

TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found in virtually all mammalian cell types. While originally isolated from the thymus gland, decades of research have revealed a far broader role in tissue homeostasis and repair [4].

In plain terms: TB-500 works primarily by regulating actin—a structural protein critical for cell movement. By controlling how actin assembles, TB-500 promotes cell migration to injury sites, supports new blood vessel growth, and reduces inflammation in preclinical models. The following sections detail specific pathways documented in peer-reviewed studies.

Actin Sequestration & Polymerization

The primary mechanism of Thymosin Beta-4 involves binding to monomeric G-actin (globular actin), preventing premature polymerization into F-actin (filamentous actin) filaments. Weber et al. (1992) demonstrated that Tβ4's primary physiological role in platelets is monomer sequestration, and that Tβ4-actin complexes do not elongate actin filaments [1]. This sequestration maintains a pool of available actin monomers that cells can rapidly deploy for cytoskeletal reorganization—a prerequisite for cell migration.

Husson et al. (2010) further characterized the beta-thymosin/WH2 actin-binding module as genuinely multifunctional, capable of G-actin sequestration, actin filament growth, nucleation, and severing depending on context [2]. This adaptability appears central to TB-500's diverse downstream effects across tissue types.

Cell Migration & Cardiac Repair

The landmark study by Bock-Marquette et al. (2004), published in Nature, demonstrated that Thymosin Beta-4 promotes myocardial and endothelial cell migration in the embryonic heart and retains this property in postnatal cardiomyocytes [3]. The study showed that Tβ4 activates integrin-linked kinase (ILK), promoting cardiac cell survival after ischemic injury. This paper established the foundation for TB-500 cardiac research.

More recently, Maar et al. (2025) showed that Thymosin Beta-4 modulates cardiac remodeling by regulating ROCK1 expression in adult mammals, demonstrating continued research interest in post-infarction applications [14]. A 2025 study by Zhang et al. further demonstrated that recombinant human thymosin beta 4 improved ischemic cardiac dysfunction in both mice and patients with acute ST-segment elevation myocardial infarction after reperfusion [15].

Anti-Inflammatory Properties

Sosne et al. (2007) demonstrated that Thymosin Beta-4 suppresses NF-κB protein levels, activation, phosphorylation, and nuclear translocation in a model of TNF-α-mediated corneal inflammation [6]. This NF-κB suppression pathway represents a documented mechanism for the anti-inflammatory effects observed across multiple tissue models.

Wei et al. (2012) showed that Tβ4 protects cardiomyocytes from oxidative stress by upregulating anti-oxidative enzymes and anti-apoptotic genes, while also modulating inflammatory mediators [11].

Angiogenesis (Blood Vessel Formation)

Philp et al. (2004) documented that Thymosin Beta-4 promotes angiogenesis in preclinical wound healing models [9]. Lv et al. (2020) further elucidated the mechanism, showing that Tβ4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF-κB pathway, with demonstrated effects on endothelial cell viability, tube formation, and migratory ability [8].

The Ac-SDKP tetrapeptide—the N-terminal metabolite of Tβ4, released by prolyl oligopeptidase cleavage—has been shown to facilitate cardiac repair after infarction by promoting endothelial cell migration and angiogenesis. Kassem et al. (2019) reviewed the Tβ4-Ac-SDKP pathway's cardiovascular relevance in detail [13].

Research Applications: Preclinical Studies

TB-500 research spans diverse tissue types and injury models. The following applications are documented in peer-reviewed literature:

Cardiac Repair Studies

Cardiac tissue repair represents TB-500's most extensively studied application. The Bock-Marquette et al. (2004) Nature paper established that Tβ4 activates ILK, promoting cardiac cell migration and survival after ischemic injury [3]. Bock-Marquette et al. (2023) reviewed decades of cardiac research, supporting the hypothesis that TB-4 facilitates post-hypoxic myocardial regeneration through multiple pathways including epicardial progenitor cell activation [10]. Zhang et al. (2025) extended these findings to a clinical setting, reporting improved cardiac function in STEMI patients treated with recombinant Tβ4 [15].

Wound Healing & Dermal Repair

TB-500's cell migration properties make it a subject of extensive wound healing research. Philp et al. (2004) documented accelerated angiogenesis and wound healing in preclinical dermal models [9]. Sosne et al. (2002) demonstrated that Tβ4 promotes wound healing and decreases inflammation in vivo following alkali injury in corneal models [5]. Hannappel (2007) reviewed the development of Tβ4 from its origins as a thymic hormone to its established role as an actin-sequestering peptide with wound healing properties [12].

Corneal Repair (Clinical-Stage Research)

Corneal injury represents one of the most advanced TB-500 research areas. Sosne et al. (2002) showed accelerated corneal epithelial healing and reduced inflammation following alkali injury in preclinical models [5]. Notably, Sosne (2018) reported that Phase 3 clinical trials using Tβ4 (as RGN-259, developed by RegeneRx Biopharmaceuticals) to treat dry eye disease and neurotrophic keratopathy were ongoing [7]. This represents the most advanced clinical development stage for any Thymosin Beta-4 application.

Neurological Repair

Chopp et al. (2015) reported that Tβ4 promotes CNS and peripheral nervous system plasticity and neurovascular remodeling, leading to neurological recovery in preclinical models of neurological disease [16]. Morris et al. (2012) demonstrated that Tβ4 improves neurological functional outcomes in rat models of embolic stroke, with effects on oligodendrocyte differentiation and neural remodeling [17].

Hair Growth

Gao et al. (2015) demonstrated that Thymosin Beta-4 induces hair growth in mouse models, with increased Tβ4 expression at mRNA and protein levels correlating with hair follicle development [18]. Philp et al. (2007) determined the mechanism involves stem cell migration and differentiation in hair follicles, with effects documented across multiple rat and mouse models including transgenic Tβ4-overexpressing mice [19].

Research context: All cited applications refer to in vitro or animal model studies unless specifically noted otherwise (e.g., the Phase 3 corneal trials [7] and the Zhang et al. 2025 cardiac study [15]). TB-500 is sold strictly for research purposes and is not approved for human or veterinary use.

TB-500 + BPC-157: The Combination Research Paradigm

Lee et al. (2021) conducted a retrospective study examining intra-articular injection of BPC-157, alone or combined with TB-500 (TB4), for multiple types of knee pain [20]. The study, covering 17 patients over a 1-year chart review (2019-2020) at the Institute for Hormonal Balance in Orlando, Florida, represents the first published examination of the BPC-157/TB-500 combination.

The rationale for combination research rests on their complementary mechanisms:

These distinct primary mechanisms address different phases of tissue repair. TB-500's actin-mediated cell migration properties [3] may complement BPC-157's angiogenic effects, and the Lee et al. study reflects growing research interest in this dual-peptide paradigm.

Vantix Bio offers both BPC-157 10mg and TB-500 10mg in protocol-optimized formats, enabling combination research from verified, batch-traceable material.

The Vantix Verification System: Batch-Level Transparency

Every TB-500 10mg vial ships with a unique Batch ID printed on the label. This identifier links directly to ISO-17025 accredited laboratory test results through our Matrix Verification Portal.

How to Verify Your Batch

  1. Locate the Batch ID on your vial label (format: VX-TB10-XXX)
  2. Visit vantixbio.com/verify
  3. Enter your Batch ID
  4. View the complete analytical record:
    • HPLC chromatogram with retention time and purity percentage
    • LC-MS/MS spectrum with observed molecular weight
    • Testing laboratory accreditation certificate
    • Optional third-party verification portal links

Storage & Reconstitution: Maintaining Peptide Integrity

Lyophilized Storage

Unopened vials: Store at -20°C (freezer). Lyophilized TB-500 generally remains stable for 24+ months when protected from moisture and light under these conditions. Goldstein et al. (2012) note that Tβ4 is a naturally stable peptide due to its lack of disulfide bonds [4].

Room temperature exposure: Standard shipping conditions (2-3 days at ambient temperature) typically do not significantly degrade lyophilized TB-500 based on peptide stability profiles. Prolonged storage above 25°C is not recommended.

Reconstitution Protocol

  1. Allow vial to reach room temperature (~10 minutes)
  2. Add bacteriostatic water slowly along the vial wall (not directly onto powder)
  3. Gently swirl—do not shake vigorously (shearing forces can damage peptide bonds)
  4. Allow 2-3 minutes for complete dissolution
  5. Concentration example: 10mg TB-500 + 2mL bacteriostatic water = 5mg/mL solution

Reconstituted Storage

Refrigerated (2-8°C): Use reconstituted TB-500 within 2-4 weeks when stored in bacteriostatic water under refrigeration.

Frozen (-20°C): Extended stability may be possible, but freeze-thaw cycles can degrade peptides. Single-use aliquots are recommended if freezing reconstituted solution.

Note on TB-500 solubility: As a larger peptide (4963 Da), TB-500 may take slightly longer to dissolve than smaller peptides like BPC-157 (~1420 Da). Patience during reconstitution is important—allow the full 2-3 minutes and continue gentle swirling until the solution is completely clear.

Frequently Asked Questions

What is the difference between TB-500 and Thymosin Beta-4?

TB-500 is a synthetic form of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein first characterized for its role in actin monomer sequestration by Weber et al. (1992) [1]. The terms are used interchangeably in research contexts, though TB-500 specifically refers to the synthetic research-grade form. CAS number 77591-33-4; molecular weight 4963 Da per PubChem CID 45382195 [PubChem].

Why is TB-500 10mg better than buying two 5mg vials?

TB-500 research commonly uses a loading/maintenance dosing paradigm—higher frequency in the first 2-4 weeks, then reduced frequency for maintenance. A 10mg vial supports both phases from a single batch, eliminating inter-batch variability as a confounding variable. At $3.50/mg with ISO-17025 verification included, this is verification-first pricing — not a discount on testing standards.

How does TB-500 differ from BPC-157?

TB-500 is a larger molecule (43 amino acids, 4963 Da) compared to BPC-157 (15 amino acids, ~1420 Da). TB-500's primary mechanism involves G-actin sequestration and cell migration [1], [3], while BPC-157 primarily promotes angiogenesis. TB-500 is most studied in cardiac repair [3], corneal healing [5], and hair growth models [18], whereas BPC-157 is more studied in tendon and GI repair models. Lee et al. (2021) examined both in combination for knee pain [20].

Can I verify TB-500 purity before purchasing?

Yes. Visit our Verification Portal and enter any recent Batch ID from the "Recent Reports" section. You'll see actual HPLC chromatograms and MS spectra from shipped batches. Every batch we sell undergoes identical ISO-17025 accredited testing—what you see in recently shipped batches reflects what you'll receive.

Related Research Guides

Explore additional forensic-grade research peptides and verification resources:

TB-500 10mg: Forensic-Grade Actin Regulation Research

ISO-17025 verified. Protocol-optimized for loading/maintenance paradigms. Batch-level transparency. Every claim cited.

Notify at Launch View Verification Portal

References

  1. Weber A, Nachmias VT, Pennise CR, Pring M, Safer D. "Interaction of thymosin beta 4 with muscle and platelet actin: implications for actin sequestration in resting platelets." Biochemistry. 1992;31(27):6179-85. PMID: 1627561
  2. Husson C, Cantrelle FX, Roblin P, et al. "Multifunctionality of the beta-thymosin/WH2 module: G-actin sequestration, actin filament growth, nucleation, and severing." Ann N Y Acad Sci. 2010;1194:44-52. PMID: 20536449
  3. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432(7016):466-72. PMID: 15565145
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. "Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications." Expert Opin Biol Ther. 2012;12(1):37-51. PMID: 22074294
  5. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD. "Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury." Exp Eye Res. 2002;74(2):293-9. PMID: 11950239
  6. Sosne G, Qiu P, Christopherson PL, Wheater MK. "Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway." Exp Eye Res. 2007;84(4):663-9. PMID: 17254567
  7. Sosne G. "Thymosin beta 4 and the eye: the journey from bench to bedside." Expert Opin Biol Ther. 2018;18(sup1):99-104. PMID: 30063853
  8. Lv S, et al. "Thymosin-beta 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF-kappaB pathway." Int J Mol Med. 2020;46(4):1347-1358. PMID: 32945357
  9. Philp D, Goldstein AL, Kleinman HK. "Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development." Mech Ageing Dev. 2004;125(2):113-5. PMID: 15037013
  10. Bock-Marquette I, Maar K, Maar S, et al. "Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies." Int Immunopharmacol. 2023;116:109741. PMID: 36709593
  11. Wei C, et al. "Thymosin beta 4 protects cardiomyocytes from oxidative stress by targeting anti-oxidative enzymes and anti-apoptotic genes." PLoS One. 2012;7(8):e42586. PMID: 22880044
  12. Hannappel E. "beta-Thymosins." Ann N Y Acad Sci. 2007;1112:21-37. PMID: 17468232
  13. Kassem KM, et al. "Tbeta4-Ac-SDKP pathway: Any relevance for the cardiovascular system?" Can J Physiol Pharmacol. 2019;97(7):589-599. PMID: 30854877
  14. Maar K, et al. "Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals." Int J Mol Sci. 2025;26(9):4131. PMID: 40362372
  15. Zhang Y, Dong Q, Bian X, et al. "Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion." Cardiovasc Res. 2025;121(17):2747-2758. PMID: 41229390
  16. Chopp M, et al. "Thymosin beta4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases." Expert Opin Biol Ther. 2015;15 Suppl 1:S9-12. PMID: 25613458
  17. Morris DC, Zhang ZG, Zhang J, et al. "Treatment of neurological injury with thymosin beta4." Ann N Y Acad Sci. 2012;1269(1):110-6. PMID: 23045978
  18. Gao X, Liang H, Hou F, et al. "Thymosin Beta-4 Induces Mouse Hair Growth." PLoS One. 2015;10(6):e0130040. PMID: 26083021
  19. Philp D, St-Surin S, Cha HJ, Moon HS, Kleinman HK, Elkin M. "Thymosin beta 4 induces hair growth via stem cell migration and differentiation." Ann N Y Acad Sci. 2007;1112:95-103. PMID: 17947589
  20. Lee E, et al. "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain." Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435

[PubChem] National Center for Biotechnology Information. "Thymosin Beta 4." PubChem Compound Database, CID 45382195. Molecular Formula: C212H350N56O78S, Molecular Weight: 4963 Da. pubchem.ncbi.nlm.nih.gov/compound/45382195

Research Compliance and Legal Status

TB-500 is intended exclusively for in vitro research and analytical reference purposes. It is not approved for human consumption, therapeutic use, or clinical application. Researchers must ensure their studies comply with institutional review board requirements, animal care protocols (if applicable), and relevant regulatory frameworks.

As with all research peptides, proper documentation, storage, and handling procedures should follow institutional biosafety and chemical safety guidelines. The forensic-grade verification we provide supports compliance documentation and quality assurance requirements for research environments.